Navigation Links
Life Sciences Leaders to Launch Statewide 'We Work for Health' Economic Development and Jobs Campaign
Date:4/20/2009

Group to Release Groundbreaking Study on Economic Impact of Life Sciences Sector on Washington State

SEATTLE, April 20 /PRNewswire/ -- An alliance of Washington state business, academic, government and community leaders will launch "We Work for Health," a landmark statewide effort to enhance the public's understanding of the economic impact of Washington's life sciences industry and to promote the growth and success of the sector.

We Work for Health will release the results of a groundbreaking study demonstrating the economic impact of the life sciences and biopharmaceutical sector in Washington state. The study will highlight the number of jobs created directly and indirectly by the biotechnology, biopharmaceutical, biomedical and research companies that make Washington an international hub for life sciences innovation.

WHAT

News conference to launch We Work for Health, a statewide economic development and jobs advocacy coalition.

Release of job creation and economic impact study by Archstone Consulting of biopharmaceutical and related industries in Washington state.

Tour of Seattle Children's Research Institute to illustrate importance of life sciences jobs in Washington state.

    WHEN
    Thursday, April 23, 2009
    10 a.m. News Conference
    10:45 a.m. Tour of Seattle Children's Research Institute with President James B. Hendricks, PhD.

    WHERE
    Seattle Children's Research Institute
    Soundgarden Room, 11th floor
    1900 9th Ave.
    Seattle, WA 98101

Complimentary parking is available in the Diamond Parking garage in the Children's building. The entrance is located in the alley off Stewart Street between 9th and Terry.

WHO

We Work for Health Co-Chairs

  • Bob Drewel, Executive Director, Puget Sound Regional Council
  • Dr. Elson S. Floyd, President, Washington State University
  • Dr. Lee Huntsman, Executive Director, Life Sciences Discovery Fund
  • Chris Rivera, President, Washington Biotechnology and Biomedical Association
  • Rogers Weed, Director of the Washington State Department of Community, Trade and Economic Development

Presenter

Michael Eckstut, Life Sciences Practice Leader, Archstone Consulting

BACKGROUND

We Work for Health is a statewide effort uniting organizations, companies, individuals and other stakeholders around a common goal: to educate policymakers and key opinion leaders about the economic impact of the life sciences innovation pipeline and to promote and grow the industry in Washington state. We Work for Health seeks to raise awareness of the impact of public policy on innovation in the life sciences, related industries and surrounding communities.

Media Contacts: Chelsea Waliser or Nate Cole-Daum, Nyhus Communications LLC for We Work for Health, (206) 323-3733 | chelsea@nyhus.com or nate@nyhus.com


'/>"/>
SOURCE We Work for Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caliper Life Sciences First Quarter 2009 Financial Results Conference Call Notice
2. Gene Network Sciences Announces Brain Cancer Collaboration With M.D. Anderson
3. HBO, UCSD Shiley-Marcos Alzheimers Disease Research Center, The Alzheimers Association San Diego/Imperial Chapter and The Neurosciences Institute Present an Advance Screening of THE ALZHEIMERS PROJECT: MOMENTUM IN SCIENCE
4. Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board
5. Advanced Life Sciences Announces Results of Shareholder Meeting and Provides Additional Information on Upcoming Advisory Committee Meeting
6. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
7. Derma Sciences Reports Fourth Quarter, Year-End Results for 2008
8. Human Pheromone Sciences Announces Fourth Quarter and Full Year Results
9. ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
10. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
11. Derma Sciences to Report 2008 Fourth Quarter and Year-End Results on April 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology: